Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Hvidovre University Hospital9 enrolled

Overview

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Type-1 Diabetes Mellitus

Interventions

glucagon like peptide -1OTHER

continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes

NaClOTHER

infusion with NaCl for 120 minutes as placebo-arm

glucose dependent insulinotropic polypeptideOTHER

continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-60 years * Type-1 diabetes diagnosed between 5-40 years of age * Normal weight(BMI 18-27), * Insulin treatment from time of diagnosis. Exclusion Criteria: * Severe complications to diabetes * Abnormal liver or kidney function * Haemoglobin below the lower limit * Macroalbuminuria * Systemic disease * Pregnancy.

Locations (1)

Dept. of Endocrinology, Hvidovre Hospital

Copenhagen, Denmark

Outcomes

Primary Outcomes

phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose

Time frame: 2 hours

Secondary Outcomes

maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine)

Time frame: 2 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.